SCHEMBL5947355

SCHEMBL5947355

COc1cccc2[nH]cc(CCNCc3cccc(OCCCF)c3)c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.58
▸ HTR6 P50406 6/20 0.57
▸ BCHE P06276 1/20 0.53
▸ HTR2A P28223 6/20 0.51
▸ HTR1A P08908 2/20 0.50
▸ DRD2 P14416 2/20 0.50
▸ HTR7 P34969 2/20 0.50
▸ MTNR1A P48039 1/20 0.50
▸ MTNR1B P49286 1/20 0.50
▸ MAPT P10636 4/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ HTR2C P28335 2/20 0.48
▸ MITF O75030 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947246 0.97 KMT2A (0.59) KMT2AHTR6BCHEHTR2AHTR1A
SCHEMBL5947711 0.91 KMT2A (0.59) KMT2AHTR6BCHEHTR2AHTR1A
SCHEMBL5947928 0.87 KMT2A (0.57) KMT2AHTR6BCHEHTR2AHTR1A
SCHEMBL5947684 0.87 KMT2A (0.57) KMT2AHTR6BCHEHTR2AHTR1A
SCHEMBL5947209 0.86 KMT2A (0.52) KMT2AHTR6BCHEHTR2AHTR1A
SCHEMBL5947679 0.86 KMT2A (0.55) KMT2AHTR6BCHEHTR2AHTR1A
SCHEMBL5947193 0.85 KMT2A (0.57) KMT2AHTR6BCHEHTR2AHTR1A
SCHEMBL5947503 0.85 KMT2A (0.64) KMT2AHTR6BCHEHTR2AHTR1A
SCHEMBL5947352 0.84 HTR6 (0.69) KMT2AHTR6BCHEHTR2AHTR1A
SCHEMBL5947178 0.84 KMT2A (0.52) KMT2AHTR6BCHEHTR2AHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed
CN-1610547-A N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor LILLY CO ELI (US) 2005-04-27 — — CN claimed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP claimed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B KMT2A 1269/4885HTR6 1/4885BCHE 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback